Related Experiment Video
Updated: Nov 17, 2025
Author Spotlight: Purifying High-Quality Tubulin to Study Protein Dynamics and Therapeutic Applications
Published on: October 11, 2024
A Rationale for Drug Design Provided by Co-Crystal Structure of IC261 in Complex with Tubulin
Jinghong Xian1, Faqian Bu1,2, Yuxi Wang2
1Department of Clinical Research Management, Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, West China Hospital, Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China.
Abstract:
Microtubules composed of α/β tubulin heterodimers are an essential part of the cytoskeleton of eukaryotic cells and are widely regarded as targets for cancer chemotherapy. IC261, which is discovered as an ATP-competitive inhibitor of serine/threonine-specific casein kinase 1 (CK1), has shown its inhibitory activity on microtubule polymerization in recent studies. However, the structural information of the interaction between tubulin and IC261 is still unclear. Here, we provided a high-resolution (2.85 Å) crystal structure of tubulin and IC261 complex, revealed the intermolecular interaction between tubulin and IC261, and analyzed the structure-activity relationship (SAR). Subsequently, the structure of tubulin-IC261 complex was compared with tubulin-colchicine complex to further elucidate the novelty of IC261. Furthermore, eight optimal candidate compounds of new IC261-based microtubule inhibitors were obtained through molecular docking studies. In conclusion, the co-crystal structure of tubulin-IC261 complex paves a way for the design and development of microtubule inhibitor drugs.
Insights
This study reveals the crystal structure of the tubulin-IC261 complex, clarifying how IC261 inhibits microtubule polymerization. This finding aids in developing new cancer chemotherapy drugs targeting microtubules.
Area of Science:
- Biochemistry
- Molecular Biology
- Structural Biology
Background:
- Microtubules, crucial for eukaryotic cell structure, are key targets in cancer chemotherapy.
- IC261, a casein kinase 1 (CK1) inhibitor, demonstrates inhibitory effects on microtubule polymerization.
- The precise interaction mechanism between tubulin and IC261 remained structurally undefined.
Purpose of the Study:
- To elucidate the high-resolution crystal structure of the tubulin-IC261 complex.
- To analyze the intermolecular interactions and structure-activity relationship (SAR) between tubulin and IC261.
- To compare the IC261-tubulin interaction with that of known inhibitors like colchicine.
Main Methods:
- X-ray crystallography to determine the 2.85 Å resolution structure of the tubulin-IC261 complex.
- Structural analysis to identify intermolecular interactions.
- Molecular docking studies to identify novel drug candidates.
Main Results:
- A high-resolution crystal structure of the tubulin-IC261 complex was obtained.
- Detailed intermolecular interactions between tubulin and IC261 were revealed.
- Eight potential new IC261-based microtubule inhibitors were identified via molecular docking.
Conclusions:
- The co-crystal structure provides critical insights into IC261's mechanism of microtubule inhibition.
- This structural information is vital for the rational design of novel microtubule-targeting anticancer agents.
- The study lays the groundwork for developing next-generation microtubule inhibitors based on the IC261 scaffold.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
01:10Drugs that Destabilize Microtubules
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...